IceCure Medical recently announced it received a patent in Japan for its cryogen pump for cryoablation procedures.
Caesarea, Israel-based IceCure Medical’s cryogenic pump is submersible in liquid nitrogen, works in a closed circuit and improves the cooling rate during a procedure. The company designed it for multiple or longer-duration procedures without needing to refill liquid nitrogen. The pump also enables temperature control of the cryoprobe, as well as the use of a wider range of cryoprobes and catheters.
“With this Notice of Allowance from the JPO, IceCure continues to build upon its leadership position in cryoablation procedures worldwide. We believe the cryogen pump will be instrumental in enabling practitioners to perform longer-term and multiple procedures more efficiently, as well as allowing for the expansion of cryoablation treatment to more clinical applications in the future,” CEO Eyal Shamir said in a news release. “This additional IP in Japan supports our distribution agreement with Terumo for our cryoablation systems in Japan.”
IceCure’s patent will be in effect until 2041. A patent for the invention has been issued in the European Union and is pending in other major markets, including the U.S.
IceCure Medical currently develops and markets ProSense, an advanced liquid nitrogen-based cryoablation therapy that treats benign and cancerous tumors by freezing. Its technology is primarily used for breast, kidney, bone and lung cancers. The minimally invasive technology could be an alternative to hospital surgical tumor removal, easily performed in a short procedure, according to the company. ProSense is marketed and sold worldwide for the indications cleared to date by the FDA and approved in Europe.